The estimated Net Worth of Gunther Birznieks is at least $5.23 Million dollars as of 4 March 2024. Mr. Birznieks owns over 17,411 units of Vanda Pharmaceuticals Inc stock worth over $1,542,759 and over the last 7 years he sold VNDA stock worth over $1,673,379. In addition, he makes $2,010,820 as Senior Vice President - Business Development at Vanda Pharmaceuticals Inc.
Sign up
Mr. Birznieks VNDA stock SEC Form 4 insiders trading
Gunther has made over 11 trades of the Vanda Pharmaceuticals Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 17,411 units of VNDA stock worth $73,300 on 4 March 2024.
The largest trade he's ever made was selling 20,465 units of Vanda Pharmaceuticals Inc stock on 1 March 2021 worth over $374,100. On average, Gunther trades about 8,060 units every 141 days since 2018. As of 4 March 2024 he still owns at least 313,569 units of Vanda Pharmaceuticals Inc stock.
You can see the complete history of Mr. Birznieks stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Gunther Birznieks biography
Gunther Birznieks is Senior Vice President - Business Development of the Company. He has served as our Senior Vice President, Business Development since March 2017 and served as our Vice President, Head of Business Development from March 2010 to March 2017. Mr. Birznieks assumed additional responsibilities in 2018 as a member of the Company’s Research and Development Committee as well as in connection with his role as the project lead for tradipitant. Prior to March 2010, Mr. Birznieks held a number of positions within Vanda, including Clinical Program Head of the tasimelteon and VSF-173 programs, Head of Informatics and in Singapore as Head of Operations. Mr. Birznieks previously spent the majority of his career in the areas of healthcare and biomedical informatics including bioinformatics support for microarray and genotyping projects with the Human Genome Project at the National Human Genome Research Institute. Prior to joining us, Mr. Birznieks founded Extropia Pte. Ltd., a Singaporean company which specialized in business and investment banking applications. Mr. Birznieks has published four books on computer technologies as well as numerous articles and talks on information security, programming, and software development life cycle. Mr. Birznieks received his Bachelor of Arts degree in psychology and his Masters of Science degree in computer science from Johns Hopkins University.
What is the salary of Gunther Birznieks?
As the Senior Vice President - Business Development of Vanda Pharmaceuticals Inc, the total compensation of Gunther Birznieks at Vanda Pharmaceuticals Inc is $2,010,820. There are 2 executives at Vanda Pharmaceuticals Inc getting paid more, with Mihael Polymeropoulos having the highest compensation of $4,278,140.
How old is Gunther Birznieks?
Gunther Birznieks is 51, he's been the Senior Vice President - Business Development of Vanda Pharmaceuticals Inc since 2017. There are 8 older and 7 younger executives at Vanda Pharmaceuticals Inc. The oldest executive at Vanda Pharmaceuticals Inc is Richard Dugan, 78, who is the Independent Director.
What's Gunther Birznieks's mailing address?
Gunther's mailing address filed with the SEC is 2200 Pennsylvania Ave NW #300e, Washington, DC 20037, USA.
Insiders trading at Vanda Pharmaceuticals Inc
Over the last 19 years, insiders at Vanda Pharmaceuticals Inc have traded over $267,060,716 worth of Vanda Pharmaceuticals Inc stock and bought 5,567,934 units worth $25,606,507 . The most active insiders traders include Kevin Ctang Capital Managem..., Nicole Vitullo, and Jesse I Treu. On average, Vanda Pharmaceuticals Inc executives and independent directors trade stock every 31 days with the average trade being worth of $546,607. The most recent stock trade was executed by Kevin Patrick Moran on 29 July 2024, trading 2,251 units of VNDA stock currently worth $13,326.
What does Vanda Pharmaceuticals Inc do?
vanda is a specialty pharmaceutical company focused on the development and commercialization of novel therapies to address high unmet medical needs and improve the lives of patients.
What does Vanda Pharmaceuticals Inc's logo look like?
Complete history of Mr. Birznieks stock trades at Vanda Pharmaceuticals Inc
Vanda Pharmaceuticals Inc executives and stock owners
Vanda Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Mihael Polymeropoulos,
President, Chief Executive Officer, Director -
Timothy Williams,
Senior Vice President, General Counsel, Secretary -
Gunther Birznieks,
Senior Vice President - Business Development -
Dr. Mihael H. Polymeropoulos M.D.,
Founder, Pres, CEO & Chairman of The Board -
Dr. Mihael H. Polymeropoulos,
Founder, Pres, CEO & Director -
Joakim Wijkstrom,
Sr. VP & Chief Marketing Officer -
Kevin Patrick Moran,
Sr. VP, CFO & Treasurer -
Timothy Williams,
Sr. VP, Gen. Counsel & Sec. -
Phaedra Chrousos,
Independent Director -
Anne Ward,
Independent Director -
H. Thomas Watkins,
Independent Chairman of the Board -
Richard Dugan,
Independent Director -
Stephen Mitchell,
Independent Director -
Aranthan Jones,
Chief Corporate Affairs and Communications Officer -
Joakim Wijkstrom,
Senior Vice President, Chief Marketing Officer -
Kevin Moran,
Acting Chief Financial Officer, Vice President, Treasurer -
Elizabeth Van Every,
Head of Corp. Affairs -
Scott L. Howell,
Chief People Officer -
Kenneth Bate,
Director -
Michael F Cola,
Director -
James E Deerfield Mgmt L.P....,
-
Paolo Baroldi,
Chief Medical Officer -
Vincent Milano,
Director -
Steven A Shallcross,
Sr. VP, CFO, Treasurer -
Albert W. Gianchetti,
Sr.VP,Chief Commercial Officer -
Tage Honore,
-
Richard L. Gulino,
SVP & General Counsel -
James Patrick Kelly,
EVP & Chief Financial Officer -
Gian Piero Reverberi,
SVP & Chief Commercial Officer -
James B Tananbaum,
Director -
Capital Ii Llccare Capital ...,
-
Robert J More,
10% owner -
Nicole Vitullo,
10% owner -
Management Co Ii Llcprospec...,
-
Brian H Dovey,
10% owner -
Deepak Shripad Phadke,
Vice President Manufacturing -
Ventures Iv Lprho Ventures ...,
-
James C Blair,
10% owner -
Inc /De Medimmune,
10% owner -
Wayne T Hockmeyer,
Director -
Ventures Iv Lprho Managemen...,
-
Vi Associates, L.P. Dp,
10% owner -
Partners Vi, L.P. Domain,
10% owner -
Venture Partners Ii Lpprosp...,
-
Jesse I Treu,
10% owner -
Sciences Investment Fund Pt...,
-
Kathleen K Schoemaker,
10% owner -
Thomas Edward Gibbs,
SVP, Chief Commercial Officer -
James E Deerfield Mgmt L.P....,
-
Howard H Pien,
Director -
Steven K Galson,
Director -
Robert Repella,
SVP & Chief Commercial Officer -
Stephanie Rast Irish,
Sr. VP, Acting CFO/Treasurer -
John Joseph Feeney,
Acting Chief Medical Officer -
Argeris N Karabelas,
Chairman of the Board -
Brian K Halak,
Director -
William D Clark,
Sr VP, Chief Business Officer -
David Russ Ramsay,
Director -
Kevin Ctang Capital Managem...,